See the source article by following the link below:
In an expanded, 3-year clinical trial of 86 patients with colorectal and 11 other cancers with so-called ‘mismatch repair’ genetic defects, scientists have found that half of the patients respond to an immunotherapy drug called pembrolizumab (Keytruda), as reported in Science.
In an expanded, 3-year clinical trial of 86 patients with colorectal and 11 other cancers with so-called ‘mismatch repair’ genetic defects, scientists have found that half of the patients respond to an immunotherapy drug called pembrolizumab (Keytruda), as reported in Science.
No comments:
Post a Comment